Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Roivant Sciences Ltd
(NQ:
ROIV
)
11.51
-0.06 (-0.56%)
Streaming Delayed Price
Updated: 2:26 PM EDT, Sep 27, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Roivant Sciences Ltd
< Previous
1
2
Next >
Roivant to Report Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2023, and Provide Business Update on Wednesday, June 28, 2023
June 26, 2023
From
Roivant Sciences
Via
GlobeNewswire
Roivant Reports Chronic Period Data for RVT-3101 from the TUSCANY-2 Phase 2b Study in Ulcerative Colitis, Demonstrating Improved Efficacy from the Induction to Chronic Period
June 22, 2023
From
Roivant Sciences
Via
GlobeNewswire
Roivant to Host Investor Call at 8:00 AM ET on Thursday, June 22 to Review Results from the Chronic Period of TUSCANY-2, a Large Global Phase 2b Study of RVT-3101 (Anti-TL1A Antibody) in Ulcerative Colitis
June 21, 2023
From
Roivant Sciences
Via
GlobeNewswire
Roivant Reports Positive Topline Results from ADORING 1, the Second Atopic Dermatitis Phase 3 Trial of VTAMA® (tapinarof) Cream, 1% in Adults and Children as Young as 2 Years Old
May 16, 2023
From
Roivant Sciences
Via
GlobeNewswire
Lokavant Hires Experienced Leaders to Accelerate Growth Trajectory
April 04, 2023
From
Lokavant
Via
Business Wire
Lokavant Emerges from Roivant Sciences with Multiple Industry Partnerships to Accelerate Impact on Clinical Research
April 04, 2023
From
Lokavant
Via
Business Wire
Covant and Boehringer Ingelheim Collaborate to Develop a Novel ADAR1 Inhibitor for Use in Cancer Patients
March 28, 2023
From
Covant Therapeutics
Via
GlobeNewswire
Roivant Reports Positive Topline Results from ADORING 2 Atopic Dermatitis Phase 3 Trial of VTAMA® (tapinarof) Cream, 1% Once Daily in Adults and Children as Young as 2 Years Old
March 15, 2023
From
Roivant Sciences
Via
GlobeNewswire
Roivant to Host Investor Call at 8:00 AM ET on Wednesday, March 15 to Review Results from ADORING 2 Phase 3 Trial in Atopic Dermatitis
March 14, 2023
From
Roivant Sciences
Via
GlobeNewswire
Proteovant Therapeutics to Present Preclinical Data from Estrogen Receptor and IKZF2 Protein Degrader Programs
March 14, 2023
PVTX-321 and PVTX-405 Achieve Development Candidate Nomination
From
Roivant Sciences
Via
GlobeNewswire
Covant Therapeutics Announces the Formation of its Scientific Advisory Board to Support Platform and Pipeline Advancement
March 07, 2023
From
Roivant Sciences
Via
GlobeNewswire
Roivant Sciences Announces Change to its Board of Directors
February 21, 2023
From
Roivant Sciences
Via
GlobeNewswire
Roivant Sciences Reports Financial Results for the Third Quarter Ended December 31, 2022 and Provides Business Update
February 13, 2023
From
Roivant Sciences
Via
GlobeNewswire
Roivant Sciences Announces Pricing of Upsized Public Offering of Common Shares
February 02, 2023
From
Roivant Sciences
Via
GlobeNewswire
Roivant Sciences Announces Proposed Public Offering of Common Shares
February 01, 2023
From
Roivant Sciences
Via
GlobeNewswire
Roivant to Report Financial Results for the Third Quarter Ended December 31, 2022 on Monday, February 13, 2023
January 30, 2023
From
Roivant Sciences
Via
GlobeNewswire
Roivant Announces Statistically Significant and Clinically Meaningful Results from the Induction Period of TUSCANY-2, a Large Global Phase 2b Study of Subcutaneous RVT-3101 for the Treatment of Ulcerative Colitis in Both the Overall and the Biomarker
January 04, 2023
From
Roivant Sciences
Via
GlobeNewswire
Roivant and Pfizer Form New Vant Company Focused on Developing TL1A Drug Candidate for Inflammatory and Fibrotic Diseases
December 01, 2022
From
Roivant Sciences
Via
GlobeNewswire
Roivant Sciences Reports Financial Results for the Second Quarter Ended September 30, 2022 and Provides Business Update
November 14, 2022
From
Roivant Sciences
Via
GlobeNewswire
Affivant to Present Data on AFVT-2101 at 37th Annual Meeting of SITC
November 10, 2022
From
Roivant Sciences
Via
GlobeNewswire
Roivant Sciences Announces Pricing of Primary and Secondary Public Equity Offering
November 08, 2022
From
Roivant Sciences
Via
GlobeNewswire
Roivant Sciences Announces Proposed Public Equity Offering
November 07, 2022
From
Roivant Sciences
Via
GlobeNewswire
Roivant Sciences to Report Financial Results for the Second Quarter Ended September 30, 2022 on Monday, November 14, 2022 and Present at Upcoming Conferences
October 18, 2022
From
Roivant Sciences
Via
GlobeNewswire
Roivant and Pfizer Unveil Priovant Therapeutics and Ongoing Registrational Studies for Oral Brepocitinib in Dermatomyositis and Lupus
June 28, 2022
From
Pfizer Inc.
Via
Business Wire
Roivant Discovery Announces 2021 Open Science Fellows
October 29, 2021
From
Roivant Discovery
Via
Business Wire
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.